JP2009542657A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009542657A5 JP2009542657A5 JP2009518225A JP2009518225A JP2009542657A5 JP 2009542657 A5 JP2009542657 A5 JP 2009542657A5 JP 2009518225 A JP2009518225 A JP 2009518225A JP 2009518225 A JP2009518225 A JP 2009518225A JP 2009542657 A5 JP2009542657 A5 JP 2009542657A5
- Authority
- JP
- Japan
- Prior art keywords
- weight percent
- ropinirole
- gel composition
- concentration
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims description 49
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims description 43
- 229960001879 ropinirole Drugs 0.000 claims description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 11
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 claims description 10
- 230000003078 antioxidant effect Effects 0.000 claims description 8
- 239000012458 free base Substances 0.000 claims description 7
- 239000003349 gelling agent Substances 0.000 claims description 7
- 239000003961 penetration enhancing agent Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 229940043348 myristyl alcohol Drugs 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 4
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 4
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 4
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 4
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000006172 buffering agent Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 238000013271 transdermal drug delivery Methods 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 2
- 239000006184 cosolvent Substances 0.000 claims 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 230000004907 flux Effects 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- -1 polyethylene Polymers 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 235000010265 sodium sulphite Nutrition 0.000 claims 1
- 239000002552 dosage form Substances 0.000 description 10
- 238000012377 drug delivery Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000016285 Movement disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- XDXHAEQXIBQUEZ-UHFFFAOYSA-N Ropinirole hydrochloride Chemical group Cl.CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 XDXHAEQXIBQUEZ-UHFFFAOYSA-N 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 208000021703 chronic tic disease Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical compound C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 description 1
- FGFUBBNNYLNVLJ-UHFFFAOYSA-N indolone Natural products C1=CC=C2C(=O)C=NC2=C1 FGFUBBNNYLNVLJ-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960002349 ropinirole hydrochloride Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81725906P | 2006-06-29 | 2006-06-29 | |
| PCT/US2007/014821 WO2008005240A2 (en) | 2006-06-29 | 2007-06-26 | Ropinirole-containing pharmaceutical compositions in the form of a gel, uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009542657A JP2009542657A (ja) | 2009-12-03 |
| JP2009542657A5 true JP2009542657A5 (enExample) | 2010-08-12 |
Family
ID=38895093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009518225A Withdrawn JP2009542657A (ja) | 2006-06-29 | 2007-06-26 | ゲルの形態でのロピニロール含有薬学的組成物、その使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20080004329A1 (enExample) |
| EP (1) | EP2032125A2 (enExample) |
| JP (1) | JP2009542657A (enExample) |
| KR (1) | KR20090031598A (enExample) |
| CN (1) | CN101478952A (enExample) |
| AR (1) | AR063201A1 (enExample) |
| AU (1) | AU2007269896A1 (enExample) |
| BR (1) | BRPI0713801A2 (enExample) |
| CA (1) | CA2654383A1 (enExample) |
| IL (1) | IL195161A0 (enExample) |
| MX (1) | MX2008015083A (enExample) |
| NO (1) | NO20085158L (enExample) |
| NZ (1) | NZ572481A (enExample) |
| PE (1) | PE20080374A1 (enExample) |
| TW (1) | TW200815045A (enExample) |
| UY (1) | UY30442A1 (enExample) |
| WO (1) | WO2008005240A2 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070212397A1 (en) * | 2005-09-15 | 2007-09-13 | Roth Daniel B | Pharmaceutical delivery device and method for providing ocular treatment |
| WO2010008600A1 (en) * | 2008-07-16 | 2010-01-21 | Dermworx Incorporated | Topical drug delivery system |
| AU2010208046B2 (en) | 2009-01-29 | 2014-10-02 | Forsight Vision4, Inc. | Posterior segment drug delivery |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| EP2431034B1 (en) * | 2009-04-24 | 2016-08-10 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch-containing package bag and method for storing adhesive patch |
| RU2547990C2 (ru) * | 2009-09-28 | 2015-04-10 | Интарсия Терапьютикс, Инк. | Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства |
| WO2013022801A1 (en) | 2011-08-05 | 2013-02-14 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| ES2608782T3 (es) | 2010-04-30 | 2017-04-17 | Teikoku Pharma Usa, Inc. | Composiciones transdérmicas de propinilaminoindano |
| CN103209664A (zh) | 2010-08-05 | 2013-07-17 | 弗赛特影像4股份有限公司 | 可植入的治疗装置 |
| AU2011285548B2 (en) | 2010-08-05 | 2014-02-06 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
| EP3861969A1 (en) | 2010-08-05 | 2021-08-11 | ForSight Vision4, Inc. | Injector apparatus for drug delivery |
| WO2012068549A2 (en) | 2010-11-19 | 2012-05-24 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| EP2688561B1 (en) | 2011-03-24 | 2018-08-22 | Teikoku Pharma USA, Inc. | Transdermal compositions comprising an active agent layer and an active agent conversion layer |
| KR101848961B1 (ko) * | 2011-05-31 | 2018-04-13 | 히사미쓰 세이야꾸 가부시키가이샤 | 로피니롤 함유 첩부제 및 그 포장체 |
| US10398592B2 (en) | 2011-06-28 | 2019-09-03 | Forsight Vision4, Inc. | Diagnostic methods and apparatus |
| PT2755600T (pt) | 2011-09-16 | 2021-04-19 | Forsight Vision4 Inc | Aparelhos de troca de fluidos |
| JP5913614B2 (ja) | 2011-11-09 | 2016-04-27 | テイコク ファーマ ユーエスエー インコーポレーテッド | 皮膚新生物の処置方法 |
| WO2013116061A1 (en) | 2012-02-03 | 2013-08-08 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
| CA2878784A1 (en) | 2012-07-12 | 2014-01-16 | Ferring B.V. | Diclofenac formulations |
| AU2013338243B2 (en) | 2012-11-02 | 2016-09-29 | Teikoku Seiyaku Co., Ltd. | Propynylaminoindan transdermal compositions |
| EP2926814B1 (en) * | 2012-11-30 | 2019-03-27 | Teikoku Seiyaku Co., Ltd. | Ropinirole-containing adhesive patch |
| WO2014152959A1 (en) | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| CN105246438B (zh) | 2013-03-28 | 2018-01-26 | 弗赛特影像4股份有限公司 | 用于输送治疗物质的眼科植入物 |
| PT2981269T (pt) | 2013-04-04 | 2023-10-10 | Boehringer Ingelheim Vetmedica Gmbh | Tratamento de distúrbios metabólicos em animais equinos |
| US9463889B2 (en) * | 2013-10-25 | 2016-10-11 | Medtronic, Inc. | Prefilled reservoir apparatus for ambulatory infusion device |
| ES2803102T3 (es) | 2014-07-15 | 2021-01-22 | Forsight Vision4 Inc | Dispositivo de administración de implante ocular |
| RU2017105844A (ru) | 2014-08-08 | 2018-09-11 | Форсайт Вижн4, Инк. | Стабильные и растворимые составы ингибиторов рецепторных тирозинкиназ и способы их получения |
| WO2016046150A1 (en) * | 2014-09-25 | 2016-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
| CN110478119B (zh) | 2014-11-10 | 2022-04-15 | 弗赛特影像4股份有限公司 | 可膨胀药物递送装置和使用方法 |
| ES2758350T3 (es) | 2015-04-15 | 2020-05-05 | Hisamitsu Pharmaceutical Co | Parche transdérmico que contiene ropinirol |
| WO2017087902A1 (en) | 2015-11-20 | 2017-05-26 | Forsight Vision4, Inc. | Porous structures for extended release drug delivery devices |
| US10966936B2 (en) | 2015-12-30 | 2021-04-06 | Corium, Inc. | Systems comprising a composite backing and methods for long term transdermal administration |
| CN113017981B (zh) | 2016-04-05 | 2023-07-25 | 弗赛特影像4股份有限公司 | 药物递送装置 |
| WO2017223402A1 (en) | 2016-06-23 | 2017-12-28 | Corium International, Inc. | Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| CN116270551A (zh) * | 2016-07-27 | 2023-06-23 | 考里安有限责任公司 | 通过盐至中性药物原位转化的组合物、透皮贴剂及应用 |
| CN111655206B (zh) | 2017-11-21 | 2022-10-14 | 弗赛特影像4股份有限公司 | 用于可扩展端口递送系统的流体交换装置及使用方法 |
| EP3930702A1 (en) | 2019-03-01 | 2022-01-05 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| KR102212722B1 (ko) * | 2019-12-23 | 2021-02-08 | 환인제약 주식회사 | 로피니롤을 포함하는 마이크로스피어 및 이를 함유하는 주사제 조성물 |
| USD1033637S1 (en) | 2022-01-24 | 2024-07-02 | Forsight Vision4, Inc. | Fluid exchange device |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| CN116763842B (zh) * | 2023-07-11 | 2025-03-04 | 海南职业技术学院 | 一种胆木浸膏凝胶剂及其制备工艺 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4452808A (en) * | 1982-12-07 | 1984-06-05 | Smithkline Beckman Corporation | 4-Aminoalkyl-2(3H)-indolones |
| DE3522550A1 (de) * | 1985-06-24 | 1987-01-02 | Klinge Co Chem Pharm Fab | Aufspruehbare pharmazeutische zubereitung fuer die topische anwendung |
| US4906463A (en) * | 1986-12-22 | 1990-03-06 | Cygnus Research Corporation | Transdermal drug-delivery composition |
| GB8712073D0 (en) * | 1987-05-21 | 1987-06-24 | Smith Kline French Lab | Medicament |
| US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5156850A (en) * | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
| GB9511366D0 (en) * | 1995-06-06 | 1995-08-02 | Smithkline Beecham Plc | Novel formulations |
| US5807570A (en) * | 1995-09-29 | 1998-09-15 | Cygnus, Inc. | Transdermal administration of ropinirole and analogs thereof |
| US6929801B2 (en) * | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
| AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
| JP2002510537A (ja) * | 1998-04-08 | 2002-04-09 | ザ ジェネラル ホスピタル コーポレーション | 薬理検査用ｍｒｉ（ｐｈｍｒｉ） |
| FR2784583B1 (fr) * | 1998-10-16 | 2002-01-25 | Synthelabo | Composition pharmaceutique a residence gastrique et a liberation controlee |
| US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6218421B1 (en) * | 1999-07-01 | 2001-04-17 | Smithkline Beecham P.L.C. | Method of promoting smoking cessation |
| US6485746B1 (en) * | 2000-08-25 | 2002-11-26 | Neurocrine Biosciences, Inc. | Controlled-release sedative-hypnotic compositions and methods related thereto |
| US20030124176A1 (en) * | 1999-12-16 | 2003-07-03 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
| CA2395993A1 (en) * | 1999-12-28 | 2001-07-05 | Ajinomoto Co., Inc. | Antidiabetic preparation for oral administration |
| US6572890B2 (en) * | 2000-01-13 | 2003-06-03 | Osmotica Corp. | Osmotic device containing venlafaxine and an anti-psychotic agent |
| SE0001151D0 (sv) * | 2000-03-31 | 2000-03-31 | Amarin Dev Ab | Method for producing a controlled-release composition |
| US20020006926A1 (en) * | 2000-04-19 | 2002-01-17 | Roylance H. H. | Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease |
| US6770297B1 (en) * | 2000-05-26 | 2004-08-03 | Unitech Pharmaceuticals, Inc. | Controlled release delivery system of solid dosage form |
| US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US6653325B2 (en) * | 2000-10-12 | 2003-11-25 | Pharmacia & Upjohn Company | Method of treating parkinson's disease |
| WO2002036077A2 (en) * | 2000-11-06 | 2002-05-10 | Andrx Pharmaceuticals, Inc. | Once a day antihistamine and decongestant formulation |
| US6656882B2 (en) * | 2001-02-28 | 2003-12-02 | Oms Investments, Inc. | Controlled release products and processes for the preparation thereof |
| AU2002248792B2 (en) * | 2001-04-18 | 2006-09-21 | Nostrum Pharmaceuticals Inc. | A novel coating for a sustained release pharmaceutical composition |
| US6833478B2 (en) * | 2001-07-13 | 2004-12-21 | Sri International | N,N-dinitramide salts as solubilizing agents for biologically active agents |
| DE10137162A1 (de) * | 2001-07-30 | 2003-02-20 | Hexal Ag | Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol |
| GB0125088D0 (en) * | 2001-10-18 | 2001-12-12 | Smithkline Beecham Cork Ltd | New use |
| US7160913B2 (en) * | 2002-09-13 | 2007-01-09 | Thomas Jefferson University | Methods and kit for treating Parkinson's disease |
| DE10250711A1 (de) * | 2002-10-31 | 2004-05-19 | Degussa Ag | Pharmazeutische und kosmetische Zubereitungen |
| US20040157910A1 (en) * | 2003-02-10 | 2004-08-12 | Smithkline Beecham Corporation | Method of treatment or prophylaxis |
| US7387788B1 (en) * | 2003-10-10 | 2008-06-17 | Antares Pharma Ipl Ag | Pharmaceutical compositions of nicotine and methods of use thereof |
| US20070048360A1 (en) * | 2005-08-23 | 2007-03-01 | R Carrara Dario N | Pharmaceutical compositions with melting point depressant agents and method of making same |
-
2007
- 2007-06-14 TW TW096121617A patent/TW200815045A/zh unknown
- 2007-06-26 EP EP07809906A patent/EP2032125A2/en not_active Withdrawn
- 2007-06-26 AU AU2007269896A patent/AU2007269896A1/en not_active Abandoned
- 2007-06-26 KR KR1020097001878A patent/KR20090031598A/ko not_active Withdrawn
- 2007-06-26 NZ NZ572481A patent/NZ572481A/en unknown
- 2007-06-26 CA CA002654383A patent/CA2654383A1/en not_active Abandoned
- 2007-06-26 BR BRPI0713801-6A patent/BRPI0713801A2/pt not_active IP Right Cessation
- 2007-06-26 MX MX2008015083A patent/MX2008015083A/es not_active Application Discontinuation
- 2007-06-26 WO PCT/US2007/014821 patent/WO2008005240A2/en not_active Ceased
- 2007-06-26 JP JP2009518225A patent/JP2009542657A/ja not_active Withdrawn
- 2007-06-26 PE PE2007000821A patent/PE20080374A1/es not_active Application Discontinuation
- 2007-06-26 CN CNA2007800229856A patent/CN101478952A/zh active Pending
- 2007-06-26 US US11/823,028 patent/US20080004329A1/en not_active Abandoned
- 2007-06-27 UY UY30442A patent/UY30442A1/es not_active Application Discontinuation
- 2007-06-28 AR ARP070102901A patent/AR063201A1/es unknown
-
2008
- 2008-11-06 IL IL195161A patent/IL195161A0/en unknown
- 2008-12-11 NO NO20085158A patent/NO20085158L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009542657A5 (enExample) | ||
| JP7145363B2 (ja) | 局所皮膜形成スプレー | |
| JP6845162B2 (ja) | ケタミン経皮送達システム | |
| CA2460140C (en) | Compositions for treatment of common cold | |
| US10179159B2 (en) | Topical anesthetic formulation | |
| EP2155175B1 (en) | Matrix-type transdermal drug delivery system and preparation method thereof | |
| JP6112867B2 (ja) | サキシトキシン誘導体での触覚の喪失の処置 | |
| WO1993009768A1 (fr) | Fomentation contenant du cetorolac | |
| CA3127926A1 (en) | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa | |
| US20080176913A1 (en) | Transdermal compositions of pramipexole having enhanced permeation properties | |
| JP2010505942A (ja) | 上皮細胞増殖因子を含有する安定な口内炎治療用液状組成物 | |
| BR0315316A (pt) | Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit | |
| AU2003240113B2 (en) | Formulation of nefopam and its use in the treatment of pain | |
| NZ564381A (en) | Transdermal method and patch for nausea comprising granisetron | |
| JP2006527234A5 (enExample) | ||
| KR101690765B1 (ko) | 항진균성 활성물질을 포함하는 경피 제제 | |
| WO2016137411A1 (en) | Topical spray composition comprising ibuprofen and lidocaine | |
| CN102137656A (zh) | 用于鼻内投予的酮咯酸医药调配物 | |
| JP2000507207A (ja) | 複合注射剤 | |
| US20170258746A1 (en) | Acetic acid/thymol compositions and their use in the treatment of onychomycosis | |
| CN108430581A (zh) | 用于利扎曲普坦的药物组合物 | |
| CN103784941A (zh) | 一种鼻用凝胶剂组合物及其制备方法 | |
| EP4647082A1 (en) | Pharmaceutical composition comprising a cgrp receptor antagonist for the treatment of acute migraine | |
| JP2006036687A (ja) | トラマドール含有外用医薬組成物 | |
| WO2025147698A1 (en) | Devices and methods for transdermal delivery of ozanimod |